Last reviewed · How we verify
MMR Bio-Manguinhos
MMR Bio-Manguinhos is a Live attenuated vaccine Biologic drug developed by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz). It is currently in Phase 3 development for Prevention of measles, mumps, and rubella in children and adults. Also known as: MMR GlaxoSmithKline.
MMR Bio-Manguinhos is a live attenuated vaccine that stimulates immune responses against measles, mumps, and rubella viruses.
MMR Bio-Manguinhos is a live attenuated vaccine that stimulates immune responses against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.
At a glance
| Generic name | MMR Bio-Manguinhos |
|---|---|
| Also known as | MMR GlaxoSmithKline |
| Sponsor | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in vaccinated individuals without causing disease, thereby triggering both humoral (antibody) and cellular immune responses. This immunological priming provides long-term protection against infection with wild-type measles, mumps, and rubella viruses.
Approved indications
- Prevention of measles, mumps, and rubella in children and adults
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Rash
- Parotitis
Key clinical trials
- Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella (PHASE2, PHASE3)
- Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (PHASE3)
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMR Bio-Manguinhos CI brief — competitive landscape report
- MMR Bio-Manguinhos updates RSS · CI watch RSS
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) portfolio CI
Frequently asked questions about MMR Bio-Manguinhos
What is MMR Bio-Manguinhos?
How does MMR Bio-Manguinhos work?
What is MMR Bio-Manguinhos used for?
Who makes MMR Bio-Manguinhos?
Is MMR Bio-Manguinhos also known as anything else?
What drug class is MMR Bio-Manguinhos in?
What development phase is MMR Bio-Manguinhos in?
What are the side effects of MMR Bio-Manguinhos?
Related
- Drug class: All Live attenuated vaccine drugs
- Manufacturer: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of measles, mumps, and rubella in children and adults
- Also known as: MMR GlaxoSmithKline
- Compare: MMR Bio-Manguinhos vs similar drugs
- Pricing: MMR Bio-Manguinhos cost, discount & access